Latest Breaking News On - Pierre fabre laboratories - Page 1 : comparemela.com

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U S FDA

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20.

United statesPascal touchonPierre fabreSecurities exchangeMemorial sloan kettering cancer centerAtara biotherapeutics incExchange commissionDrug administrationBiologics license applicationChief executive officerObjective response rateSecurities actSecurities exchange actPierre fabre laboratoriesMiddle eastSouthern california

Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U S FDA

CASTRES, France, May 20, 2024 /PRNewswire/ Pierre Fabre Laboratories today announce the submission by Atara Biotherapeutics (ATARA), a leader in T-cell

United statesMidi pyréesPierre fabreAdriana herreraLaurence marchalPierre fabre pharmaceuticals incDrug administrationFirst allogeneict cell therapyTab cel wouldFirst approved therapyPierre fabre pharmaceuticalsPierre fabre laboratoriesBiologics license applicationChief executive officerPierre fabre medical careLaboratories media contact

ATARA Biotherapeutics (ATRA) Submits Tabelecleucel BLA for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

ATARA Biotherapeutics (ATRA) Submits Tabelecleucel BLA for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomPierre fabrePascal touchonDrug administrationHealthcare products regulatory agencyAtara biotherapeutics incMemorial sloan kettering cancer centerEuropean commissionBiologics license applicationChief executive officerObjective response rateBreakthrough therapy designationPierre fabre laboratoriesMiddle east

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesPascal touchonPierre fabreProgram in nonCorporate communications investor relationsInternational society for cell gene therapyAtara biotherapeutics incSecurities exchangeProgram in lupus nephritisProgram in severe systemic lupus erythematosusExchange commissionChief executive officerPost transplant lymphoproliferative diseaseBiologics license applicationObjective response rateLupus nephritis

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndrome

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndrome
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Midi pyréesSouth koreaRepublic of koreaPrnewswire pierre fabreAnne kerveillantDennis riedlEuropean unionUrovant sciences gmbCommittee for medicinal products human useEuropean commissionEuropean medicines agencyUrovant sciencesSumitomo pharma america incFabre laboratoriesMedicinal productsHuman use